Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $8.00 Consensus PT from Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been given an average rating of “Buy” by the seven ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $7.75.

Several brokerages have recently commented on PSTV. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Plus Therapeutics in a research report on Friday, October 31st. Wall Street Zen upgraded Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. D Boral Capital raised Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Finally, Zacks Research raised Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th.

Insider Buying and Selling

In related news, Director Robert P. Lenk bought 110,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was purchased at an average cost of $0.49 per share, with a total value of $53,900.00. Following the transaction, the director owned 139,327 shares in the company, valued at approximately $68,270.23. This trade represents a 375.08% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On Plus Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Plus Therapeutics during the 1st quarter valued at approximately $38,000. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics in the 2nd quarter valued at approximately $41,000. Finally, Altium Capital Management LLC bought a new stake in shares of Plus Therapeutics during the third quarter valued at approximately $628,000. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Stock Performance

Shares of PSTV stock opened at $0.54 on Friday. The company has a market capitalization of $53.41 million, a P/E ratio of -0.24 and a beta of 0.77. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.31. The stock has a 50 day moving average price of $0.57 and a two-hundred day moving average price of $0.50.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.50 million. As a group, equities analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.